Company: PFSA
Filing Date: 2025-02-12
Form Type: S-4/A
Source: 0001213900-25-012354
Chunk: 79

Company: Profusa, Inc.
Filing Date: 2025-02-12
Form: S-4/A
Chunk 79
---
 should keep in mind that the Sponsor and NorthView’s directors, officers and initial stockholders have interests in the Business Combination that are different from, or in addition to, the interests of NorthView stockholders generally. Please see the section entitled 14 “ Proposal 1 — The Business Combination Proposal — Interests of NorthView’s Directors, and Officers and Initial Stockholders in the Business Combination” for additional information. The NorthView Board was aware of and considered these interests, among other matters, in evaluating and negotiating the Transactions and in recommending to the NorthView stockholders that they vote “FOR” the proposals presented at the Special Meeting. On December20, 2024, NorthView received a delisting determination letter from Nasdaq as the 36 -monthanniversary from its IPO has passed on December27, 2024, and NorthView’s securities were suspended from trading and delisted from Nasdaq. As of the same date, NorthView’s securities started being quoted on OTC Pink. There could be substantial risks to NorthView and New Profusa as a result of NorthView’s non -compliancewith this rule. See “ Risk Factors — Risks Related to NorthView and the Business Combination.” This could have significant material adverse consequences on NorthView and its securities, including that it will negatively impact its ability to complete a business combination, will limit investors’ ability to make transactions in its securities and could subject it to additional trading restrictions. Risk Factors This proxy statement/prospectus provides you with detailed information about the Business Combination and related transactions. You are encouraged to carefully read the entire document and the documents incorporated by reference. IN PARTICULAR, YOU SHOULD CAREFULLY CONSIDER THE MATTERS DISCUSSED UNDER “RISK FACTORS” BEGINNING ON PAGE 25. Some of the risks related to Profusa, NorthView, and New Profusa are summarized below: Risks Related to Profusa •Profusa and its auditors have substantial doubt about Profusa’s ability to continue as a going concern, which may hinder Profusa’s ability to obtain further financing. •Profusa has a limited operating history on which to assess the prospects for its business and it has incurred losses since inception. Profusa anticipates that it will continue to incur significant losses for at least the next several years as it continues to commercialize its existing products and services and seeks to develop and commercialize new products and services. •The clinical trial process is lengthy and expensive with uncertain outcomes. Results of earlier studies may not be predictive of future clinical